IP Library Granted Patent US 10,132,797
Granted Patent B2
US 10,132,797 · App. 15/847,697 · Granted Nov 20, 2018

Profiling peptides and methods for sensitivity profiling

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 10,132,797
App. No.
15/847,697
Granted
Nov 20, 2018
Kind
B2
Abstract

The present disclosure is generally directed to profiling peptides, compositions, and kits, as well as methods of use thereof. The profiling peptides comprise an Mcl-1 binding domain, and optionally a cellular uptake moiety. The methods of using such profiling peptides include predicting sensitivity of a cancer, selecting a treatment, treating a cancer, producing a sensitivity profile, and the like.

Claims (17)

1. A profiling peptide comprising the sequence of SEQ ID NO:14.

2. A composition comprising a profiling peptide comprising the sequence of SEQ ID NO:14 and a carrier.

3. The profiling peptide of claim 1 , consisting of the sequence of SEQ ID NO:14.

4. The composition of claim 2 , wherein the profiling peptide consists of the sequence of SEQ ID NO:14.

5. The composition of claim 2 , further comprising a cancer cell.

6. The composition of claim 5 , wherein the cancer cell is a cell of a hematologic cancer.

7. The composition of claim 6 , wherein the hematologic cancer is multiple myeloma, myelodysplastic syndrome (MDS), acute myeloid leukemia (AML), acute lymphoblastic leukemia (ALL), acute lymphocytic leukemia, chronic lymphogenous leukemia, chronic lymphocytic leukemia (CLL), mantle cell lymphoma, diffuse large B-cell lymphoma, follicular lymphoma, or non-Hodgkin's lymphoma.

8. A kit comprising:

a profiling peptide comprising the sequence of SEQ ID NO:14;

and a detecting agent.

9. The kit of claim 8 , further comprising a positive control and a negative control.

10. The kit of claim 9 , wherein the positive control is carbonyl cyanide m-chlorophenyl hydrazone (CCCP).

11. The kit of claim 8 , further comprising written instructions.

12. The kit of claim 8 , wherein the detecting agent is a dye.

13. The kit of claim 8 , wherein the dye is a 3,3′-Dihexyloxacarbocyanine Iodide (DiOC 6 ).

14. The kit of claim 8 , wherein the dye is a potentiometric dye.

15. The kit of claim 8 , wherein the profiling peptide consists of the sequence of SEQ ID NO:14.

Assignments (4)
CHANGE OF NAME Recorded Apr 27, 2022
From: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
To: SUMITOMO PHARMA ONCOLOGY, INC.
Reel/Frame 059809/0557 →
MERGER Recorded Jul 10, 2020
From: TOLERO PHARMACEUTICALS, INC.
To: BOSTON BIOMEDICAL, INC.
Reel/Frame 053181/0114 →
CHANGE OF NAME Recorded Jul 10, 2020
From: BOSTON BIOMEDICAL, INC.
To: SUMITOMO DAINIPPON PHARMA ONCOLOGY, INC.
Reel/Frame 053181/0133 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 15, 2018
From: BEARSS, DAVID J.; SIDDIQUI-JAIN, ADAM; WHATCOTT, CLIFFORD J.; PETERSON, PETER W.; WARNER, STEVEN L.; MOURITSEN, LARS
To: TOLERO PHARMACEUTICALS, INC.
Reel/Frame 045238/0259 →